The details of the presentations are as follows:
ETX2514 Presentations:
Oral Presentation: Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Adult Subjects
Session: 529 – Real Time Tissue Pharmacokinetic Monitoring
Date and Time: June 11, 2018 11:30 AM – 11:45 AM
Location: A410
Poster #517: Plasma and IntrapulmonaryConcentrations of ETX2514 and Sulbactam in Healthy Adult Subjects
Session: 409 – AAR04 – Antimicrobial PK/PD & General Pharmacology: Clinical Studies
Date and Time: June 10, 2018 12:45 PM – 2:45 PM
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster #604: Restoration of Sulbactam Activity by the Novel β-lactamase inhibitor ETX2514 against recent clinical isolates of Acinetobacter baumannii, including extensively drug-resistant (XDR) isolates expressing OXA-237
Session: 062 – AAR08 – New Antimicrobial Agents and New Research Technologies: New β-lactamase Inhibitors and Inhibitor Combinations
Date and Time: June 8, 2018 11:00 AM – 1:00 PM
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster #605: The combination of ETX2514, a novel diazabicyclooctenone β-lactamase inhibitor (BLI), and sulbactam overcomes carbapenem resistant Acinetobacter baumannii (CRAB)
Session: 062 – AAR08 – New Antimicrobial Agents and New Research Technologies: New β-lactamase Inhibitors and Inhibitor Combinations
Date and Time: June 8, 2018 11:00 AM – 1:00 PM
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster #606: Evaluation of Pharmacokinetics/Pharmacodynamics of the novel β-lactamase inhibitor, ETX2514, in combination with sulbactam against Acinetobacter baumannii
Session: 062 – AAR08 – New Antimicrobial Agents and New Research Technologies: New β-lactamase Inhibitors and Inhibitor Combinations
Date and Time: June 8, 2018 11:00 AM – 1:00 PM
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster #1103: Structural Analyses of Inhibition of OXA-24 and ADC-7 β-lactamases by ETX2514, A Novel Diazabicyclooctenone β-lactamase Inhibitor (BLI)
Session: 097 – MBP16 – Structural Biology
Date and Time: June 8, 2018 11:00 AM – 1:00 PM
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
ETX0282 Presentation:
Poster #603: The novel β-lactamase inhibitor ETX1317 effectively restores the activity of cefpodoxime against extended spectrum β-lactamase (ESBL)- and carbapenemase-expressing Enterobacteriaceae isolated from recent urinary tract infections
Session: 062 – AAR08 – New Antimicrobial Agents and New Research Technologies: New β-lactamase Inhibitors and Inhibitor Combinations
Date and Time: June 8, 2018 11:00 AM – 1:00 PM
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Discovery Platform Presentation:
Oral Presentation: Addressing the Challenge of Gram-negative Permeation in Antibacterial Discovery
Session: 123 – Riddles and Rules of Gram-negative Permeation
Date and Time: June 8, 2018 1:30 PM – 2:15 PM
Location: Exhibit and Poster Hall, Building B, Halls B2-B5, AAR Hub
About ETX2514SUL
ETX2514 is a novel broad-spectrum intravenous inhibitor of class A, C and D β-lactamases. ETX2514 restores the in vitro activity of multiple β-lactams against Gram-negative, multidrug-resistant pathogens. Entasis is initially developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of a variety of serious multidrug-resistant infections caused by A. baumannii. Sulbactam is a generic β-lactam that has intrinsic antibacterial activity against A. baumannii but suffers from widespread β-lactamase-mediated resistance. In preclinical studies, ETX2514 restored sulbactam antibacterial activity against A. baumannii. ETX2514 has completed single- and multi-ascending dose Phase 1 trials. The U.S. Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to ETX2514SUL for the treatment of hospital-acquired and ventilator-acquired bacterial pneumonia and bloodstream infections due to A. baumannii.
About ETX0282CPDP
ETX0282 is an orally available, broad spectrum inhibitor of Class A and C beta-lactamases. Entasis is developing ETX0282 in combination with cefpodoxime, an orally available cephalosporin approved for treatment of a variety of bacterial infections. Cefpodoxime’s clinical utility is currently limited by beta-lactamase-mediated resistance. In preclinical studies, ETX0282 restored cefpodoxime’s antimicrobial activity against a variety of pathogens, including Enterobacteriaceae resistant to fluoroquinolones, cephalosporins and carbapenems. Entasis is initially developing ETX0282CPDP, the combination of ETX0282 and cefpodoxime, for the treatment of infections caused by Enterobacteriaceae, including multidrug-resistant and carbapenem-resistant Enterobacteriaceae (CRE). ETX0282CPDP is partially supported by an award from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program (CARB-X).
About Entasis Therapeutics Inc.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
About CARB-X
CARB-X is the world’s largest public-private partnership devoted to early stage antibacterial research and development. Funded by ASPR/BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X is investing up to $455 million from 2016-2021 to support innovative products from ‘hit-to-lead’ phase through to Phase 1 clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio and the California Life Sciences Institute (CLSI). For more information, visit www.carb-x.org.
This press release is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award from Wellcome Trust, as administrated by CARB-X. The contents are solely the responsibility of the authors and do not necessarily represent the official views of CARB-X, the HHS Office of the Assistant Secretary for Preparedness and Response, the National Institutes of Health or Wellcome Trust.
